Stockscreener 앱 받기
2.15
8.59%
0.17
전일 마감가:
$1.98
열려 있는:
$1.95
하루 거래량:
105.80K
Relative Volume:
1.61
시가총액:
$72.30M
수익:
-
순이익/손실:
$-28.32M
주가수익비율:
-0.2028
EPS:
-10.6039
순현금흐름:
$-15.52M
1주 성능:
+19.11%
1개월 성능:
+50.35%
6개월 성능:
-29.97%
1년 성능:
-56.30%
1일 변동 폭
$1.831
$2.15
1주일 범위
$1.73
$2.15
52주 변동 폭
$1.28
$9.50
Dogwood Therapeutics Inc Stock (DWTX) Company Profile
명칭
Dogwood Therapeutics Inc
전화
(866) 620-8655
주소
44 MILTON AVENUE, ALPHARETTA
Compare DWTX vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DWTX
Dogwood Therapeutics Inc
|
2.15 | 64.74M | 0 | -28.32M | -15.52M | -10.60 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Dogwood Therapeutics Inc 주식(DWTX)의 최신 뉴스
Dogwood Therapeutics, Inc. 2026: Revenue ($14.06M), EPS ($0.34) — 10-Q Summary - TradingView
Dogwood Therapeutics (DWTX) logs $16.5M H1 loss and warns on going concern outlook - Stock Titan
Armistice Capital (DWTX) discloses 9.99% Dogwood Therapeutics ownership in 13G/A - Stock Titan
Dogwood Therapeutics (NASDAQ:DWTX) Releases Earnings Results, Misses Estimates By $0.21 EPS - MarketBeat
Form 8K Dogwood Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Dogwood Therapeutics Reports $11.5 Million Second-Quarter Net Loss - Quiver Quantitative
Dogwood Therapeutics reports Q2 2026 net loss of $11.5M, IPR&D charge of $9.19M; $9.6M cash - TradingView
DWTX: Halneuron Phase 2b trial nears completion as Q2 net loss widens on higher R&D and impairment - TradingView
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results - The Manila Times
Pain drug trial enrolls 217 as Dogwood expects fall 2026 results - Stock Titan
Dogwood Therapeutics Inc (DWTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Dogwood Therapeutics Inc (DWTX) Stock News Today - tradingkey.com
Dogwood Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Dogwood Therapeutics (DWTX) to Release Quarterly Earnings on Wednesday - MarketBeat
Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 4.3%What's Next? - MarketBeat
Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipeline - Bitget
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Surprise - dars.gov.et
Dogwood Therapeutics, Inc. Revenue Breakdown – NASDAQ:DWTX - TradingView
Dogwood Therapeutics Inc (DWTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
Dogwood Therapeutics Inc (DWTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
DWTX|Dogwood Therapeutics Inc|Price:1.530|Chg%:+0.030 - TradingKey
Dogwood Therapeutics Market Sentiment - Benzinga España
Dogwood Therapeutics Inc (DWTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dogwood Therapeutics Inc (DWTX) Balance Sheet - TradingKey
Dogwood Therapeutics Inc (DWTX) Income Statement - TradingKey
Dogwood Therapeutics Inc (DWTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: Narrower Net Loss Exceeds Consensus Expectations Amid Clinical DevelopmentFinal Results - dars.gov.et
TradingKey - TradingKey
Dogwood Therapeutics Inc (DWTX) Valuation: PE, PB & Fair Value Analysis - tradingkey.com
Dogwood Therapeutics Inc (DWTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dogwood Therapeutics Enrolls First 200 Patients in Phase 2b Neuropathic Pain Trial - marketscreener.com
Dogwood (DWTX) Reaches Enrollment Milestone in HAL-CINP Phase 2b Trial - GuruFocus
Dogwood Therapeutics enrolls 200 patients in pain treatment trial - Investing.com
Dogwood Reports 4.5% Early Termination Rate Among First 200 Patients - Stock Titan
Enterprise value to revenue forward of Dogwood Therapeutics, Inc. – NASDAQ:DWTX - TradingView
Dogwood Therapeutics (DWTX) Slips 1% as Shares Test Support Near $1.36Ratio Spread Trade - dars.gov.et
Dogwood Therapeutics (DWTX) Slips Modestly, Holds Above Key Support LevelBull Flag - dars.gov.et
Dogwood Therapeutics (DWTX) Edges Higher Amid Tight Trading RangeRSI Overbought Alerts - dars.gov.et
Dogwood Therapeutics (DWTX) Holds Steady at $1.42 – Key Levels in FocusBuffered ETF - dars.gov.et
Virios Therapeutics weighs strategic options as development focus remains on fibromyalgia - Ad-hoc-news.de
Dogwood Therapeutics (DWTX) Rises 4.35% as Stock Climbs Toward Resistance LevelThrowback Trade - dars.gov.et
Price to sales forward of Dogwood Therapeutics, Inc. – NASDAQ:DWTX - TradingView
Enterprise value to EBIT forward of Dogwood Therapeutics, Inc. – NASDAQ:DWTX - TradingView
Price to earnings forward of Dogwood Therapeutics, Inc. – NASDAQ:DWTX - TradingView
DWTXDogwood Therapeutics Inc Latest SEC Filings - Finviz
Dogwood Therapeutics Names OrbiMed’s Iain Dukes Chair of Scientific Advisory Board - citybiz
Dogwood Therapeutics appoints Iain Dukes to lead advisory board - Investing.com
Dogwood Therapeutics appoints Iain Dukes to lead advisory board By Investing.com - Investing.com Nigeria
Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board - GlobeNewswire
Dogwood Therapeutics, Inc.(NasdaqCM:DWTX) added to Russell Microcap Value Benchmark Index - marketscreener.com
Dogwood Therapeutics, Inc.(NasdaqCM: DWTX) added to Russell Microcap Index - marketscreener.com
Dogwood Therapeutics Inc (DWTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):